Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period

Expert Opinion on Pharmacotherapy

Volumn 18, Issue 13, 2017, Pages 1291-1300

  Kadowaki, Takashi ^a   Kondo, Kazuoki ^b   Sasaki, Noriyuki ^b   Miyayama, Kyoko ^b   Yokota, Shoko ^b   Terata, Ryuji ^b   Gouda, Maki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

combination; Diabetes mellitus; drug therapy; insulin; Japanese; teneligliptin; type 2

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; TENELIA; TENELIGLIPTIN; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; PYRAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIABETIC PATIENT; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; JAPANESE (PEOPLE); KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN; DRUG EFFECTS; JAPAN; MULTIMODALITY CANCER THERAPY;

BLOOD GLUCOSE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET THERAPY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXERCISE THERAPY; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; MALE; MIDDLE AGED; PYRAZOLES; THIAZOLIDINES;

EID: 85027176163     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2017.1359259     Document Type: Article

References (33)

1. IDF Diabetes Atlas 2015-7th Edition. International Diabetes Federation; 2015. Available at:http://www.diabetesatlas.org/.
2. Yabe D, Seino Y, Fukushima M, et al. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15(6):602.
3. Ko SH, Kim DJ, Park JH, et al. Task force team for diabetes fact sheet of the Korean diabetes association. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013:nationwide population-based cohort study. Medicine (Baltimore). 2016;95(27):e4018.
4. Kohro T, Yamazaki T, Sato H, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54(2):93–97.
5. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367(4):319–328.•• The ORIGIN study showed that early insulin treatment attenuates glucotoxicity and slows the progression of β cell dysfunction.
6. Ryan EA, Imes S, Wallace C., Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27(5):1028–1032.
7. Wajchenberg BL., Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187–218.
8. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004;27(11):2597–2602.
9. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes:a multicenter randomised parallel-group trial. Lancet. 2008;371(9626):1753–1760.
10. Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes:CSI study. Diabetes Obes Metab. 2012;14(9):795–802.
11. Rehman MB, Tudrej BV, Soustre J, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes:meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2017;43(1):48–58.
12. Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes:focus on East Asian perspectives. J Diabetes Investig. 2016;7(Suppl 1):102–109.
13. Hinnen D. Dipeptidyl peptidase-4 inhibitors in diverse patient populations with type 2 Diabetes. Diabetes Educ. 2015;41(1 Suppl):19S–31S.
14. de Wit HM, Te Groen M, Rovers MM, et al. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors:a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(1):301–314.
15. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting:systematic review and meta-analysis. BMJ. 2012;344:e1369.
16. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors:meta-analysis and systematic review. Clin Ther. 2012;34(6):1247–1258.e22.
17. Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus:a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2012;14:1040–1046.
18. Tanaka S, Suzuki K, Aoki C, et al. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes Technol Ther. 2014;16(12):840–845.• This article showed that TNL added to insulin ameliorated glucose fluctuation on the 24-h glucose profile without increasing hypoglycemia, as measured by continuous glucose monitoring in Japanese patients.
19. Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4(6):576–584.
20. Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus:a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab. 2014;16(5):418–425.
21. Fa.Kyorin.co.jp. The treatment guide for diabetes 2014-2015. Chapter 6. Pharmacotherapy, B Types of Insulin Preparations; p 33–34. Japan Diabetes Society. Japan; [cited 2017 Jul10]. Available from http://www.fa.kyorin.co.jp/jds/uploads/Treatment_Guide_for_Diabetes_2014-2015.pdf
22. Kadowaki T, Marubayashi F, Yokota S, et al. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus:a pooled analysis of two Phase III clinical studies. Expert Opin Pharmacother. 2015;16(7):971–981.
23. Kim MK, Rhee EJ, Han KA, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus:a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab. 2015;17(3):309–312.
24. Otsuka Y, Yamaguchi S, Furukawa A, et al. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes. Endocr J. 2015;62(2):133–143.
25. Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes:meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011;13(7):594–603.
26. Kim YG, Min SH, Hahn S, et al. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes:a systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;116:86–95.
27. Chen C, Yu Q, Zhang S, et al. Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes:a meta-analysis. Int J Clin Exp Pathol. 2015;8(11):14141–14150.
28. Min SH, Yoon JH, Hahn S, et al. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes:a systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev. 2016 May 7 Epub ahead of print. DOI:10.1002/dmrr.2818.
29. Mitsubishi Tanabe Pharma Corp. Tenelia® tablets 20 mg Package Insert 2012.
30. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245–254.
31. Ahrén B. Avoiding hypoglycemia:a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013;9:155–163.
32. Matsuba I, Sawa T, Kawata T, et al. Cross-national variation in glycemic control and diabetes-related distress among east asian patients using insulin:results from the MOSAIc study. Diabetes Ther. 2016;7(2):349–360.
33. Polinski JM, Kim SC, Jiang D, et al. Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use:understanding the challenges associated with progression of therapy (MOSAIc). BMC Endocr Disord. 2015;15:46.